含比斯穆特的四重疗法用于消除Helicobacter pylori:一个随机的10天和14天临床试验
Yu-Ming Ding1,2,3, Miao Duan1,2,3, Zhong-Xue Han1,2,3
1Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, No. 107, Wenhuaxi Road, Jinan, 250012, Shandong, China.
Digestive diseases and sciences
|May 3, 2024
概括
与14天治疗相比,为期10天的含木四次治疗方案有效地消除了Helicobacter pylori (H. pylori),显示出非劣质的疗效和较少的副作用. 这种较短的持续时间为H. pylori根除提供了安全且耐受良好的选择.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 含比斯的四重疗法是一种标准的第一线治疗,用于根除Helicobacter pylori (H. pylori).
- 这种治疗的最佳持续时间尚未确定,这导致正在进行的研究.
- 比较10天和14天的治疗方案对于优化H. pylori治疗策略至关重要.
研究的目的:
- 为了比较10天与14天含有斯木斯的四倍疗法的疗效和安全性,用于H. pylori根除.
- 为了确定更短的治疗持续时间是否会影响根除率或不良事件概况.
- 为H. pylori治疗持续时间提供基于证据的建议.
主要方法:
- 一项多中心随机对照研究,涉及中国1300名先前未接受过治疗的H. pylori患者.
- 患者被随机分配,接受10天或14天的含木四重治疗方案.
- 在治疗后至少6周,使用13C尿素呼吸试验评估了H. pylori的根除.
主要成果:
- 每项方案的根除率为10天组的93.22%和14天组的93.74% (p < 0.001).
- 意图治疗的根除率分别为88.62%和89.38% (p = 0.007).
- 副作用的发生率在10天组 (22.59%) 与14天组 (28.50%,p = 0.016) 相比显著较低.
结论:
- 十天的含有比斯穆特的四倍疗法在有效性方面与14天的治疗方案对H. pylori根除无差.
- 10天的治疗方案与较低的副作用发生率有关,表明更好的耐受性.
- 10天的治疗方案是H. pylori根除的安全,有效和推的选择.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
379
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
379
01:26Peptic Ulcer Disease IV: Management
89
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
89
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
115
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
115
01:23Gastritis III: Clinical Manifestations and Management
232
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
232
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
393
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
393
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
432
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
432